Nick Paul Taylor
The Odyssey Therapeutics story is progressing quickly. Ten months after disclosing a $218 million series A, the Gary Glick-helmed biotech is back with another mega round as it prepares to push candidates into clinic-enabling studies next year.
Glick, Ph.D., who made his name setting up and running biotechs such as Lycera, IFM Therapeutics and Scorpion Therapeutics, founded Odyssey in 2021 and rounded up a deep-pocketed syndicate of investors to support his plans. By the time Glick publicly unveiled Odyssey late last year, the biotech had raised $218 million and built a 100-person team to advance seven candidates toward the clinic.